

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

August 2022

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white and grey wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 August 2022.....	3
Section H changes to Part II	7
Index.....	16

Summary of decisions

EFFECTIVE 1 AUGUST 2022

- Aqueous cream (Boucher) crm 500 g – delisting delayed
- Bisacodyl (Bisacodyl Viatrix) tab 5 mg – new listing and addition of PSS
- Bisacodyl (Pharmacy Health) tab 5 mg – to be delisted 1 January 2023
- Budesonide with eformoterol powder for inhalation 200 mcg with eformoterol fumarate 6 mcg (Symbicort Turbuhaler) and powder for inhalation 400 mcg with eformoterol fumarate 12 mcg (Symbicort Turbuhaler) – new listing
- Bupivacaine hydrochloride with fentanyl (Bupafen) inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag and 200 ml bag, 10 inj pack – new listing and addition of PSS
- Bupivacaine hydrochloride with fentanyl (Bupafen) inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag and 200 ml bag, 5 inj pack – to be delisted 1 January 2023
- Cefalexin (Flynn) grans for oral liquid 25 mg per ml and 50 mg per ml, 100 ml – new listing and addition of PSS
- Cefalexin (Cefalexin Sandoz) grans for oral liquid 25 mg per ml and 50 mg per ml, 100 ml – to be delisted 1 January 2023
- Clobetasol propionate (Dermol) crm 0.05% and oint 0.05%, 30 g and scalp app 0.05%, 30 ml – price increase and addition of PSS
- Dexamfetamine sulfate (Aspen) tab 5 mg – new listing
- Digoxin tab 62.5 mcg (Lanoxin PG) and tab 250 mcg (Lanoxin) – price increase and addition of PSS
- Durvalumab (Imfinzi) inj 50 mg per ml 2.4 ml and 10 ml vial – new listing
- Enteral feed 1.5 kcal/ml (e.g. Nutrison Energy Multi Fibre) liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag – to be delisted 1 July 2023
- Enteral feed 1 kcal/ml (e.g. Nutrison Multi Fibre) liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag – to be delisted 1 July 2023
- Enteral liquid peptide formula (Nutrini Peptisorb) liquid 2.75 g protein, 13.7 g carbohydrate and 3.89 g fat per 100 ml, 500 ml – to be delisted 1 July 2023
- Extensively hydrolysed formula powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can (AllerPro Syneo 1), powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can (AllerPro Syneo 2) and powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can (e.g. Pepti-Junior) – new listing

Summary of decisions – effective 1 August 2022 (continued)

- Extensively hydrolysed formula powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can (Aptamil AllerPro SYNEO 1), powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can (Aptamil AllerPro SYNEO 2) and powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can (e.g. Aptamil Gold+ Pepti-Junior) – to be delisted 1 November 2022
- Ferrous sulfate (Ferrograd) tab long-acting 325 mg (105 mg elemental) – price decrease and addition of PSS
- Ferrous sulfate (Ferodan) oral liq 30 mg (6 mg elemental) per ml, 500 ml – price increase and addition of PSS
- Fludarabine phosphate (Fludarabine Ebewe) inj 50 mg vial – price increase and addition of PSS
- Furosemide [frusemide] (Furosemide-Baxter) inj 10 mg per ml, 2 ml ampoule – price increase and addition of PSS
- Gefitinib (Iressa) tab 250 mg – price decrease
- High fat formula (Ketocal 4:1 (Unflavoured and vanilla)) powder 14.3 g protein, 2.8 g carbohydrate and 69.2 g fat per 100 g, can, 300 g – new listing
- High fat formula (Ketocal 4:1 (Unflavoured and vanilla)) powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can, 300 g – to be delisted 1 March 2023
- Ibuprofen tab 200 mg – 12, 24 and 48 tablet pack – delisted 1 August 2022
- Lidocaine [lignocaine] hydrochloride spray 10% (Xylocaine) and gel 2%, 11 ml urethral syringe (Instillagel Lido) – price increase and addition of PSS
- Lidocaine [lignocaine] hydrochloride with adrenaline (Xylocaine) inj 1% with adrenaline 1:100,000, 5 ml ampoule – price increase and addition of PSS
- Loperamide hydrochloride (Diamide Relief) cap 2 mg – price increase and addition of PSS
- Losartan potassium with hydrochlorothiazide (Arrow-Losartan & Hydrochlorothiazide) tab 50 mg with hydrochlorothiazide 12.5 mg – price decrease and addition of PSS
- Low-GI enteral feed 1 kcal/ml (e.g. Nutrison Advanced Diason) liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag – to be delisted 1 July 2023
- Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride (Glycoprep-O) powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet – new listing and addition of PSS

Summary of decisions – effective 1 August 2022 (continued)

- Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride (Glycoprep-C) powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g and 210 g sachet – to be delisted 1 November 2022
- Olaparib (Lynparza) tab 100 mg and 150 mg – amended restriction criteria
- Omeprazole inj 40 mg ampoule with diluent (Dr Reddy's Omeprazole) and inj 40 mg vial (Omezol IV) – price increase and addition of PSS
- Paediatric enteral feed 1 kcal/ml (e.g. Nutrini RTH) liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag – to be delisted 1 July 2023
- Paediatric enteral feed 1.5 kcal/ml (e.g. Nutrini Energy RTH) liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag – to be delisted 1 July 2023
- Paracetamol with codeine (Paracetamol + Codeine (Relieve)) tab paracetamol 500 mg with codeine phosphate 8 mg – price increase and addition of PSS
- Paroxetine (Loxamine) tab 20 mg – price increase and addition of PSS
- Paroxetine (Loxamine) tab 20 mg – Pharmacode 2626799 to be delisted 1 January 2023
- Phenoxyethylpenicillin (penicillin v) (AFT) grans for oral liq 125 mg per 5 ml and 250 mg per 5 ml, 100 ml – price increase and addition of PSS
- Prednisolone acetate (Prednisolone-AFT) eye drops 1%, 10 ml – price increase
- Procaine penicillin (Cilicaine) inj 1.5 g in 3.4 ml syringe – to be delisted 1 February 2023
- Propofol (Fresofol 1% MCT/LCT) inj 10 mg per ml, 20 ml ampoule, 50 ml and 100 ml vial – addition of PSS
- Rocuronium bromide (Hameln) inj 10 mg per ml, 5 ml ampoule – price increase and addition of PSS
- Ropinirole hydrochloride (Ropin) tab 0.25 mg, 1 mg, 2 mg and 5 mg – price increase and addition of PSS
- Roxithromycin (Rulide D) tab dispersible 50 mg – delisting delayed
- Sodium chloride (Fresenius Kabi) inj 0.9%, 5 ml ampoule – price increase and addition of PSS
- Sodium chloride (Fresenius Kabi) inj 0.9%, 10 ml ampoule – price decrease and addition of PSS
- Sodium chloride (Fresenius Kabi) inj 0.9%, 20 ml ampoule – addition of PSS
- Sotalol (Mylan) tab 80 mg and 160 mg – price increase and addition of PSS

Summary of decisions – effective 1 August 2022 (continued)

- Tamsulosin hydrochloride (Tamsulosin-Rex) cap 400 mcg – price increase and addition of PSS
- Tenoxicam (Tilcotil) tab 20 mg – price increase and addition of PSS
- Water (Fresenius Kabi) inj 20 ml ampoule – addition of PSS
- Water (Multichem) inj 20 ml ampoule – to be delisted 1 January 2023
- Zoledronic acid (Zoledronic acid Viatrix) inj 4 mg per 5 ml, vial – new listing

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

Section H changes to Part II

Effective 1 August 2022

ALIMENTARY TRACT AND METABOLISM

5	LOPERAMIDE HYDROCHLORIDE (↑ price and addition of PSS) Cap 2 mg – 5% DV Jan-23 to 2025.....	7.25	400	Diamide Relief
8	OMEPRAZOLE (↑ price and addition of PSS) Inj 40 mg ampoule with diluent – 5% DV Jan-23 to 2025.....	37.38	5	Dr Reddy's Omeprazole Omezol IV
	Inj 40 mg vial – 5% DV Jan-23 to 2025.....	11.95	5	
13	MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE (new listing) Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet – 5% DV Aug-22 to 1-Jan-2024.....	13.68	3	Glycoprep-0
13	MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE (delisting) Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet – 5% DV Jan-22 to 2024 31-Jul-2022.....	218.88	48	Glycoprep-C
	Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet <i>e.g. Glycoprep-C</i> Note – Glycoprep-C powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g and 210 g sachet to be delisted from 1 November 2022.			
15	BISACODYL (new listing and addition of PSS) Tab 5 mg – 5% DV Jan-23 to 2025.....	5.80	200	Bisacodyl Viatrix
	Note – Pharmacy Health tab 5 mg to be delisted from 1 January 2023.			
22	FERROUS SULFATE (↓ price and addition of PSS) Tab long-acting 325 mg (105 mg elemental) – 5% DV Jan-23 to 2025.....	2.55	30	Ferrograd
22	FERROUS SULFATE (↑ price and addition of PSS) Oral liq 30 mg (6 mg elemental) per ml – 5% DV Jan-23 to 2025.....	13.10	500 ml	Ferodan

BLOOD AND BLOOD FORMING ORGANS

40	SODIUM CHLORIDE (↑ price and addition of PSS) Inj 0.9%, 5 ml ampoule – 5% DV Jan-23 to 2025.....	4.00	20	Fresenius Kabi
40	SODIUM CHLORIDE (↓ price and addition of PSS) Inj 0.9%, 10 ml ampoule – 5% DV Jan-23 to 2025.....	5.25	50	Fresenius Kabi

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2022 (continued)

40	SODIUM CHLORIDE (addition of PSS) Inj 0.9%, 20 ml ampoule – 5% DV Jan-23 to 2025	5.00	20	Fresenius Kabi
41	WATER (addition of PSS and delisting) Inj 20 ml ampoule – 5% DV Jan-23 to 2025	5.00	20	Fresenius Kabi
	Note – Multichem inj 20 ml ampoule to be delisted from 1 January 2023.			

CARDIOVASCULAR SYSTEM

43	LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE (↓ price and addition of PSS) Tab 50 mg with hydrochlorothiazide 12.5 mg – 5% DV Jan-23 to 2025	4.00	30	Arrow-Losartan & Hydrochlorothiazide
44	DIGOXIN (↑ price and addition of PSS) Tab 62.5 mcg – 5% DV Jan-23 to 2025	7.80	240	Lanoxin PG
	Tab 250 mcg – 5% DV Jan-23 to 2025	16.90	240	Lanoxin
46	SOTALOL (↑ price and addition of PSS) Tab 80 mg – 5% DV Jan-23 to 2025	37.50	500	Mylan
	Tab 160 mg – 5% DV Jan-23 to 2025	14.00	100	Mylan
47	FUROSEMIDE [FRUSEMIDE] (↑ price and addition of PSS) Inj 10 mg per ml, 2 ml ampoule – 5% DV Jan-23 to 2025	2.40	5	Furosemide-Baxter

DERMATOLOGICALS

58	AQUEOUS CREAM (delisting delayed) Crm 500 g	1.73	500 g	Boucher
	Note: DV limit applies to the pack sizes of greater than 100 g. Note – Boucher crm 500 g delisting delayed until 1 October 2022.			
59	CLOBETASOL PROPIONATE (↑ price and addition of PSS) Crm 0.05% – 5% DV Jan-23 to 2025	2.40	30 g	Dermol
	Oint 0.05% – 5% DV Jan-23 to 2025	2.33	30 g	Dermol
61	CLOBETASOL PROPIONATE (↑ price and addition of PSS) Scalp app 0.05% – 5% DV Jan-23 to 2025	6.26	30 ml	Dermol

GENITO-URINARY SYSTEM

65	TAMSULOSIN HYDROCHLORIDE (↑ price and addition of PSS) → Cap 400 mcg – 5% DV Jan-23 to 2025	22.31	100	Tamsulosin-Rex
----	---	-------	-----	-----------------------

HORMONE PREPARATIONS

68	ZOLEDRONIC ACID (new listing) → Inj 4 mg per 5 ml, vial	18.00	1	Zoledronic acid Viatrix
----	--	-------	---	--------------------------------

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

Changes to Section H Part II – effective 1 August 2022 (continued)

INFECTIONS

79	CEFALEXIN (new listing and addition of PSS) Grans for oral liq 25 mg per ml – 5% DV Jan-23 to 2024 7.88	100 ml	Flynn
	Grans for oral liq 50 mg per ml – 5% DV Jan-23 to 2024 10.38	100 ml	Flynn
	Note – Cefalexin Sandoz grans for oral liq 25 mg per ml and 50 mg per ml to be delisted from 1 January 2023.		
81	ROXITHROMYCIN (delisting delayed) → Tab dispersible 50 mg 8.29	10	Rulide D
	Note – Rulide D tab dispersible 50 mg brand only delisting delayed until 1 March 2023.		
82	PHENOXYMETHYLPENICILLIN [PENICILLIN V] († price and addition of PSS) Grans for oral liq 125 mg per 5 ml – 5% DV Jan-23 to 2025 3.40	100 ml	AFT
	Grans for oral liq 250 mg per 5 ml – 5% DV Jan-23 to 2025 4.24	100 ml	AFT
82	PROCAINE PENICILLIN (delisting) Inj 1.5 g in 3.4 ml syringe 123.50	5	Cilicaine
	Note – Cilicaine inj 1.5 g in 3.4 ml syringe, brand only to be delisted from 1 February 2023.		

MUSCULOSKELETAL SYSTEM

107	ROCURONIUM BROMIDE († price and addition of PSS) Inj 10 mg per ml, 5 ml ampoule – 5% DV Jan-23 to 2025 37.06	10	Hameln
109	IBUPROFEN (delisted) Tab 200 mg – 12 tablet pack Tab 200 mg – 24 tablet pack Tab 200 mg – 48 tablet pack		
	Note – Ibuprofen tab 200 mg – 12, 24 and 48 tablet pack delisted from 1 August 2022.		

NERVOUS SYSTEM

109	TENOXCAM († price and addition of PSS) Tab 20 mg – 5% DV Jan-23 to 2025 18.50	100	Tilcotil
111	ROPINIROLE HYDROCHLORIDE († price and addition of PSS) Tab 0.25 mg – 5% DV Jan-23 to 2025 4.05	84	Ropin
	Tab 1 mg – 5% DV Jan-23 to 2025 4.95	84	Ropin
	Tab 2 mg – 5% DV Jan-23 to 2025 6.48	84	Ropin
	Tab 5 mg – 5% DV Jan-23 to 2025 14.50	84	Ropin
112	PROPOFOL (addition of PSS) Inj 10 mg per ml, 20 ml ampoule – 5% DV Jan-23 to 2025 4.35	5	Fresofol 1% MCT/LCT
	Inj 10 mg per ml, 50 ml vial – 5% DV Jan-23 to 2025 19.50	10	Fresofol 1% MCT/LCT
	Inj 10 mg per ml, 100 ml vial – 5% DV Jan-23 to 2025 39.00	10	Fresofol 1% MCT/LCT

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2022 (continued)

112	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL (new pack size listing and addition of PSS) Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 5% DV Jan-23 to 2025	245.00	10	Bupafen
	Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 5% DV Jan-23 to 2025	255.00	10	Bupafen
	Note – Bupafen inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml and 200 ml bag, 5 inj pack to be delisted from 1 January 2023.			
113	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↑ price and addition of PSS) Spray 10% – 5% DV Jan-23 to 2025	78.95	50 ml	Xylocaine
	Gel 2%, 11 ml urethral syringe – 5% DV Jan-23 to 2025	59.50	10	Instillagel Lido
113	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE (↑ price and addition of PSS) Inj 1% with adrenaline 1:100,000, 5 ml ampoule – 5% DV Jan-23 to 2025	32.00	10	Xylocaine
117	PARACETAMOL WITH CODEINE (↑ price and addition of PSS) Tab paracetamol 500 mg with codeine phosphate 8 mg – 5% DV Jan-23 to 2025	27.50	1,000	Paracetamol + Codeine (Relieve)
119	PAROXETINE (↑ price and addition of PSS) Tab 20 mg – 5% DV Jan-23 to 2025	4.11	90	Loxamine
119	PAROXETINE (delisting) Tab 20 mg.....	3.61	90	Loxamine
	Note – Pharmacode 2626799 to be delisted from 1 January 2023.			
130	DEXAMFETAMINE SULFATE (new listing) → Tab 5 mg.....	28.50	100	Aspen

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

138	FLUDARABINE PHOSPHATE (↑ price and addition of PSS) Inj 50 mg vial – 5% DV Jan-23 to 2025	634.00	5	Fludarabine Ebewe
141	OLAPARIB (amended restriction criteria) → Tab 100 mg.....	3,701.00	56	Lynparza
	→ Tab 150 mg.....	3,701.00	56	Lynparza

Restricted - Ovarian cancer

Initiation

Medical Oncologist

Re-assessment required after 12 months

Either:

1 Patient is currently on treatment with olaparib and met all remaining criteria (criterion 2) below prior to commencing treatment; or

2 All of the following:

2.1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and

2.2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and

~~3 Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and~~

~~4 Patient has platinum-sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and~~

continued...

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Brand or Generic Manufacturer
------------------------------------	-------------------------------------

Changes to Section H Part II – effective 1 August 2022 (continued)

continued...

~~5 Patient's disease must have achieved partial or complete response to treatment with the immediately preceding platinum-based regimen; and~~

~~6 Patient's disease has not progressed following prior treatment with olaparib; and~~

~~7 Treatment will be commenced within 8 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and~~

2.3 Either:

2.3.1 All of the following:

2.3.1.1 Patient has newly diagnosed, advanced disease; and

2.3.1.2 Patient has received one line of previous treatment with platinum-based chemotherapy; and**

2.3.1.3 Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen; or

2.3.2 All of the following:

2.3.2.1 Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and**

2.3.2.2 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and**

2.3.2.3 Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen; and

2.3.2.4 Patient has not previously received funded olaparib treatment; and

2.4 Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and

2.5 Treatment to be administered as maintenance treatment; and

2.6 Treatment not to be administered in combination with other chemotherapy.

Continuation - Ovarian cancer

Medical Oncologist

Re-assessment required after 12 months

All of the following:

1 Treatment remains clinically appropriate and patient is benefitting from treatment; and

~~2 No evidence of progressive disease; and~~

~~3 Treatment to be administered as maintenance treatment; and~~

~~4 Treatment not to be administered in combination with other chemotherapy~~

2 Either:

2.1 No evidence of progressive disease; or

2.2 Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion; and

3 Treatment to be administered as maintenance treatment; and

4 Treatment not to be administered in combination with other chemotherapy; and

5 Either:

5.1 Both:

5.1.1 Patient has received one line of previous treatment with platinum-based chemotherapy; and**

5.1.2 Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years; or

5.2 Patient has received at least two lines of previous treatment with platinum-based chemotherapy.**

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

****A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.**

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2022 (continued)

146	GEFITINIB (↓ price) → Tab 250 mg.....	918.00	30	Iressa
213	DURVALUMAB (new listing) → Inj 50 mg per ml, 2.4 ml vial → Inj 50 mg per ml, 10 ml vial	1,128.00 4,700.00	1 1	Imfinzi Imfinzi
	Restriction			
	Initiation - Non-small cell lung cancer			
	Medical oncologist			
	<i>Re-assessment required after 3 months</i>			
	Either:			
	1 Patient is currently on treatment with durvalumab and met all remaining criteria (criterion 2) below prior to commencing treatment; or			
	2 All of the following:			
	2.1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); and			
	2.2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and			
	2.3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and			
	2.4 Patient has a ECOG performance status of 0 or 1; and			
	2.5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and			
	2.6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and			
	2.7 Either:			
	2.7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or			
	2.7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and			
	2.8 Treatment with durvalumab to cease upon signs of disease progression.			
	Continuation - Non-small cell lung cancer			
	Medical oncologist			
	<i>Re-assessment required after 3 months</i>			
	All of the following:			
	1 The treatment remains clinically appropriate and the patient is benefitting from treatment; and			
	2 Either:			
	2.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or			
	2.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and			
	3 Treatment with durvalumab to cease upon signs of disease progression; and			
	4 Total continuous treatment duration must not exceed 12 months.			

RESPIRATORY SYSTEM AND ALLERGIES

225	BUDESONIDE WITH EFORMOTEROL (new listing) Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg.....	33.74	120 dose	Symbicort Turbuhaler
	Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg.....	33.74	60 dose	Symbicort Turbuhaler

SENSORY ORGANS

230	PREDNISOLONE ACETATE (↑ price) Eye drops 1%	6.92	10 ml	Prednisolone- AFT
-----	--	------	-------	-------------------

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

Changes to Section H Part II – effective 1 August 2022 (continued)

SPECIAL FOODS

252	LOW-GI ENTERAL FEED 1 KCAL/ML (delisting) → Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Advanced Diason</i>
	Note – Nutrison Advanced Diason liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag to be delisted from 1 July 2023.			
256	ENTERAL LIQUID PEPTIDE FORMULA (delisting) → Liquid 2.75 g protein, 13.7 g carbohydrate and 3.89 g fat per 100 ml	10.45	500 ml	Nutrini Peptisorb
	Note – Nutrini Peptisorb liquid 2.75 g protein, 13.7 g carbohydrate and 3.89 g far per 100 ml, 500 ml to be delisted from 1 July 2023.			
257	EXTENSIVELY HYDROLYSED FORMULA (new listing) → Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can	30.42	900 g	AllerPro Syneo 1
	→ Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can	30.42	900 g	AllerPro Syneo 2
	→ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can			<i>e.g. Pepti-Junior</i>
257	EXTENSIVELY HYDROLYSED FORMULA (delisting) → Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can	30.42	900 g	Aptamil AllerPro SYNEO 1
	→ Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can	30.42	900 g	Aptamil AllerPro SYNEO 2
	→ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can			<i>e.g. Aptamil Gold+ Pepti Junior</i>
	Note – Aptamil AllerPro Syneo 1 powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can 1, Aptamil AllerPro Syneo 2 powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can and Aptamil Gold+ Pepti-Junior powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can to be delisted from 1 November 2022.			
259	HIGH FAT FORMULA (new listing) → Powder 14.3 g protein, 2.8 g carbohydrate and 69.2 g fat per 100 g, can.....	35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)
259	HIGH FAT FORMULA (delisting) → Powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can.....	35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)
	Note – Ketocal 4:1 (unflavoured and vanilla) powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can, 300 g to be delisted from 1 March 2023.			

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 August 2022 (continued)

- 260 PAEDIATRIC ENTERAL FEED 1 KCAL/ML (delisting)
 → Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml,
 500 ml bag *e.g. Nutrini RTH*
 Note – Nutrini RTH liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag to be delisted from 1 July 2023.
- 260 PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML (delisting)
 → Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml,
 500 ml bag *e.g. Nutrini Energy RTH*
 Note – Nutrini Energy RTH liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag to be delisted from 1 July 2023.
- 262 ENTERAL FEED 1.5 KCAL/ML (delisting)
 → Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g
 fibre per 100 ml, 1,000 ml bag *e.g. Nutrison Energy
Multi Fibre*
 Note – Nutrison Energy Multi Fibre liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag to be delisted from 1 July 2023.
- 262 ENTERAL FEED 1 KCAL/ML (delisting)
 → Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g
 fibre per 100 ml, 1000 ml bag *e.g. Nutrison Multi
Fibre*
 Note – Nutrison Multi Fibre liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag to be delisted from 1 July 2023.

Effective 1 July 2022

INFECTIONS

- 95 REMDESIVIR (new listing)
 Note: Remdesivir to be provided to Health NZ Hospitals at a cost of \$0.00 as stock has been purchased directly by Pharmac
 → Inj 100 mg vial..... 760.57 1 Veklury
 Restricted
 Initiation – Treatment of mild to moderate COVID-19
 Only if patient meets antiviral access criteria (as per <https://pharmac.govt.nz/covid-oral-antivirals>). Note the supply of treatment is via Pharmac’s approved distribution process. Refer to the Pharmac website for more information about this and stock availability.
 Initiation – COVID-19 in hospitalised patients
 Therapy limited to 5 doses
 All of the following:
 1 Patient is hospitalised with confirmed (or probable) symptomatic COVID-19; and
 2 Patient is considered to be at high risk of progression to severe disease; and
 3 Patient’s symptoms started within the last 7 days; and
 4 Patient does not require, or is not expected to require, mechanical ventilation; and
 5 Not to be used in conjunction with other funded COVID-19 antiviral treatments; and
 6 Treatment not to exceed five days.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

Changes to Section H Part II – effective 1 July 2022 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

203	SOTROVIMAB (new listing) → Inj 62.5 mg per ml, 8 ml vial 0.00	1	Xevudy
	Restricted Initiation Only if patient meets access criteria (as per https://pharmac.govt.nz/sotrovimab). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability.		
204	TIXAGEVIMAB WITH CILGAVIMAB (new listing) → Inj 100 mg per 1.5 ml vial with cilgavimab 100 mg per 1.5 ml vial 0.00	1	Evusheld
	Restricted Initiation Only if patient meets access criteria (as per https://pharmac.govt.nz/Evusheld). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability.		

VACCINES

269	INFLUENZA VACCINE (amended restriction criteria – new criteria shown only) → Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) 110.00	10	Afluria Quad (2022 Formulation)
	Restricted Initiation – Serious mental health conditions or addiction Any of the following: 1 schizophrenia; or 2 major depressive disorder; or 3 bipolar disorder; or 4 schizoaffective disorder; or 5 person is currently accessing secondary or tertiary mental health and addiction services. Initiation – children from 3 to 12 years of age (inclusive) Children 3 to 12 years of age (inclusive) from 1 July 2022 to 31 December 2022.		

Index

Pharmaceuticals and brands

A			
Afluria Quad (2022 Formulation).....	15	Imfinzi.....	12
AllerPro Syneo 1	13	Influenza vaccine.....	15
AllerPro Syneo 2	13	Instillagel Lido.....	10
Aptamil AllerPro SYNEO 1	13	Iressa	12
Aptamil AllerPro SYNEO 2	13	K	
Aptamil Gold+ Pepti Junior.....	13	Ketocal 4:1 (Unflavoured).....	13
Aqueous cream.....	8	Ketocal 4:1 (Vanilla).....	13
Arrow-Losartan & Hydrochlorothiazide	8	L	
B		Lanoxin.....	8
Bisacodyl.....	7	Lanoxin PG	8
Bisacodyl Viatris	7	Lidocaine [Lignocaine] hydrochloride	10
Budesonide with eformoterol	12	Lidocaine [Lignocaine] hydrochloride with adrenaline.....	10
Bupafen	10	Lignocaine	10
Bupivacaine hydrochloride with fentanyl	10	Loperamide hydrochloride.....	7
C		Losartan potassium with hydrochlorothiazide.....	8
Cefalexin.....	9	Low-gi enteral feed 1 kcal/ml	13
Cilicaine.....	9	Loxamine.....	10
Clobetasol propionate.....	8	Lynparza.....	10
D		M	
Dermol.....	8	Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride.....	7
Dexamfetamine sulfate	10	N	
Diamide Relief.....	7	Nutrini Energy RTH.....	14
Digoxin	8	Nutrini Peptisorb	13
Dr Reddy's Omeprazole.....	7	Nutrini RTH	14
Durvalumab	12	Nutrison Advanced Diason	13
E		Nutrison Energy Multi Fibre.....	14
Enteral feed 1.5 kcal/ml.....	14	Nutrison Multi Fibre	14
Enteral feed 1 kcal/ml.....	14	O	
Enteral liquid peptide formula.....	13	Olaparib	10
Evusheld	15	Omeprazole.....	7
Extensively hydrolysed formula.....	13	Omezol IV	7
F		P	
Ferodan	7	Paediatric enteral feed 1.5 kcal/ml	14
Ferrograd	7	Paediatric enteral feed 1 kcal/ml.....	14
Ferrous sulfate	7	Paracetamol + Codeine (Relieve).....	10
Fludarabine Ebewe	10	Paracetamol with codeine	10
Fludarabine phosphate	10	Paroxetine.....	10
Fresofol 1% MCT/LCT	9	Penicillin V	9
Frusamide.....	8	Pepti-Junior	13
Furosemide-Baxter	8	Phenoxymethylpenicillin [Penicillin V]	9
Furosemide [Frusamide].....	8	Prednisolone acetate.....	12
G		Prednisolone- AFT.....	12
Gefitinib	12	Procaine penicillin	9
Glycoprep-C.....	7	Propofol.....	9
Glycoprep-O	7	R	
H		Remdesivir.....	14
High fat formula	13	Rocuronium bromide	9
I		Ropin.....	9
Ibuprofen	9		

Index

Pharmaceuticals and brands

Ropinirole hydrochloride.....	9	Tilcotil.....	9
Roxithromycin.....	9	Tixagevimab with cilgavimab.....	15
Rulide D.....	9	V	
S		Veklury.....	14
Sodium chloride.....	7, 8	W	
Sotalol.....	8	Water.....	8
Sotrovimab.....	15	X	
Symbicort Turbuhaler.....	12	Xevudy.....	15
T		Xylocaine.....	10
Tamsulosin hydrochloride.....	8	Z	
Tamsulosin-Rex.....	8	Zoledronic acid.....	8
Tenoxicam.....	9	Zoledronic acid Viatrix.....	8

New Zealand
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1172-3694 (Print)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand